Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents

A kind of technology of remyelination and demyelination, used in demyelinating diseases and disorders and/or the composition and compound field of reducing paralysis

Active Publication Date: 2007-04-04
ELAN PHARM INC
View PDF62 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There are currently no effective treatments for MS

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
  • Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
  • Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[1301] Compound preparation

[1302] The compounds of the present invention can be easily prepared from available starting materials using the following general-purpose process. It should be understood that although typical or preferred process conditions (ie, reaction temperature, time, molar ratio of reactants, solvent, pressure, etc.) are given, other conditions may also be used unless otherwise specified. The optimal reaction conditions can vary according to the specific reactants or solvents used, but those skilled in the art can determine these conditions by providing routine optimization procedures.

[1303] In addition, those skilled in the art should understand that conventional protecting groups may be required to prevent undesirable reactions of certain functional groups. Protecting groups suitable for different functional groups and conditions suitable for the protection and deprotection of particular functional groups are well known in the art. For example, various pr...

Embodiment 1

[1395] Prepare hard gelatin capsules containing the following components:

[1396] quality

[1397] Ingredients (mg / capsule)

[1398] Active component 30.0

[1399] Starch 305.0

[1400] Magnesium stearate 5.0

[1401] The above components were mixed and filled into hard gelatin capsules at 340 mg of bright.

Embodiment 2

[1403] The following components are used to prepare tablets:

[1404] quality

[1405] Ingredients (mg / capsule)

[1406] Active ingredient 25.0

[1407] Cellulose, microcrystalline 200.0

[1408] Colloidal silica 10.0

[1409] Stearic acid 5.0

[1410] The components are mixed and compressed into tablets, each weighing 240 mg.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Affinityaaaaaaaaaa
Login to View More

Abstract

The present application provides methods and compositions for inhibiting demyelination, promoting remyelination, and / or treating paralysis in a subject in need thereof. Preferably, when administered to a patient in an amount effective to inhibit demyelination and / or promote remyelination, the composition includes immunoglobulins (such as antibodies, antibody fragments, and recombinantly produced antibodies or fragments), Polypeptides (such as soluble forms of ligand proteins for integrins) and small molecules. The compositions and methods may also employ other anti-inflammatory drugs that have been used to alleviate conditions and diseases associated with demyelination.

Description

Technical field [0001] The present invention generally relates to compositions and compounds that can be used to treat demyelinating diseases and disorders in patients and / or reduce paralysis. Background technique [0002] Inflammation is the response of vascularized tissue to infection or injury and is affected by the adhesion of white blood cells to endothelial cells of blood vessels and their infiltration into surrounding tissues. In normal inflammation, infiltrating white blood cells release toxic mediators to kill invading organisms, swallow debris and dead cells, and play a role in tissue repair and immune response. However, in pathological inflammation, infiltrating white blood cells over-respond and can cause severe or lethal damage. See, for example, Hickey, Psychoneuroimmunology II (Academic Press 1990). [0003] Integrins are a family of cell surface glycoproteins involved in cell adhesion, immune cell migration and activation. Alpha-4 integrin is e...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K6/00A61K39/395
Inventor S·J·卡利克M·A·普莱斯A·W·康拉迪F·S·格兰特C·M·塞姆科D·德雷森E·梅塞尔史密斯S·弗里德曼T·耶德诺克
Owner ELAN PHARM INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products